- Home
- ACRS vs VPV Comparison
ACRS vs VPV Comparison
Compare ACRS & VPV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- VPV
- Stock Information
- Founded
- ACRS 2012
- VPV 1993
- Country
- ACRS United States
- VPV United States
- Employees
- ACRS N/A
- VPV N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- VPV Trusts Except Educational Religious and Charitable
- Sector
- ACRS Health Care
- VPV Finance
- Exchange
- ACRS Nasdaq
- VPV Nasdaq
- Market Cap
- ACRS 165.7M
- VPV 183.2M
- IPO Year
- ACRS 2015
- VPV N/A
- Fundamental
- Price
- ACRS $1.95
- VPV $10.36
- Analyst Decision
- ACRS Strong Buy
- VPV
- Analyst Count
- ACRS 9
- VPV 0
- Target Price
- ACRS $9.25
- VPV N/A
- AVG Volume (30 Days)
- ACRS 822.9K
- VPV 36.6K
- Earning Date
- ACRS 11-05-2025
- VPV 01-01-0001
- Dividend Yield
- ACRS N/A
- VPV 3.60%
- EPS Growth
- ACRS N/A
- VPV N/A
- EPS
- ACRS N/A
- VPV N/A
- Revenue
- ACRS $16,789,000.00
- VPV N/A
- Revenue This Year
- ACRS N/A
- VPV N/A
- Revenue Next Year
- ACRS $7.02
- VPV N/A
- P/E Ratio
- ACRS N/A
- VPV N/A
- Revenue Growth
- ACRS N/A
- VPV N/A
- 52 Week Low
- ACRS $1.05
- VPV $8.58
- 52 Week High
- ACRS $5.17
- VPV $10.28
- Technical
- Relative Strength Index (RSI)
- ACRS 56.00
- VPV 72.64
- Support Level
- ACRS $1.81
- VPV $10.25
- Resistance Level
- ACRS $2.16
- VPV $10.41
- Average True Range (ATR)
- ACRS 0.12
- VPV 0.07
- MACD
- ACRS -0.03
- VPV 0.03
- Stochastic Oscillator
- ACRS 41.43
- VPV 90.57
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About VPV Invesco Pennsylvania Value Municipal Income Trust (DE)
Invesco Pennsylvania Value Municipal Income Trust is a diversified, closed-end management investment company. The investment objective is to provide common shareholders with a high level of current income exempt from federal and Pennsylvania income taxes and, where possible under local law, local income and personal property taxes, consistent with preservation of capital.